TrinityPoint Wealth LLC Has $4.41 Million Position in Merck & Co., Inc. (NYSE:MRK)

TrinityPoint Wealth LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 46.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,818 shares of the company's stock after selling 34,127 shares during the period. TrinityPoint Wealth LLC's holdings in Merck & Co., Inc. were worth $4,408,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of Merck & Co., Inc. by 10.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 55,281 shares of the company's stock worth $7,332,000 after acquiring an additional 5,088 shares during the last quarter. Quent Capital LLC raised its holdings in Merck & Co., Inc. by 11.4% during the 1st quarter. Quent Capital LLC now owns 10,236 shares of the company's stock worth $1,351,000 after buying an additional 1,048 shares during the period. PAX Financial Group LLC lifted its stake in Merck & Co., Inc. by 10.1% during the first quarter. PAX Financial Group LLC now owns 3,408 shares of the company's stock valued at $450,000 after buying an additional 314 shares in the last quarter. Hilltop Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 0.9% in the first quarter. Hilltop Partners LLC now owns 10,653 shares of the company's stock worth $1,406,000 after buying an additional 97 shares during the period. Finally, Capitolis Liquid Global Markets LLC raised its holdings in shares of Merck & Co., Inc. by 18.3% during the first quarter. Capitolis Liquid Global Markets LLC now owns 86,700 shares of the company's stock valued at $11,440,000 after acquiring an additional 13,400 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Performance

NYSE MRK traded down $0.85 during trading on Monday, hitting $95.46. The company's stock had a trading volume of 2,942,461 shares, compared to its average volume of 8,883,931. Merck & Co., Inc. has a 52 week low of $94.48 and a 52 week high of $134.63. The firm has a market cap of $241.48 billion, a P/E ratio of 20.08, a price-to-earnings-growth ratio of 1.38 and a beta of 0.40. The firm has a 50 day moving average price of $108.84 and a 200 day moving average price of $118.83. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.07. The business had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. Merck & Co., Inc.'s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Equities research analysts forecast that Merck & Co., Inc. will post 7.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRK has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $130.00 to $123.00 and set an "equal weight" rating for the company in a research note on Friday, November 1st. Barclays dropped their price target on Merck & Co., Inc. from $142.00 to $140.00 and set an "overweight" rating on the stock in a research report on Monday, October 7th. Wells Fargo & Company lowered their target price on Merck & Co., Inc. from $125.00 to $110.00 and set an "equal weight" rating on the stock in a research note on Friday, November 1st. BMO Capital Markets reduced their price target on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Finally, Wolfe Research began coverage on shares of Merck & Co., Inc. in a research report on Friday. They set a "peer perform" rating on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $130.86.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.